| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
GJ-103 free acid targets the nonsense-mediated decay pathway. It induces readthrough of premature stop codons, allowing for the production of full-length proteins in cells with nonsense mutations. This is its primary mechanism of action.
|
|---|---|
| ln Vitro |
In vitro, GJ-103 free acid induces readthrough of premature stop codons. It has shown preclinical activity against various cancer cell lines, demonstrating its ability to interfere with tumor progression. Its activity is assessed by measuring the production of full-length proteins.
|
| ln Vivo |
In AT153LA cells that are homozygous for TGA mutation and homozygous for TAA mutation, GJ103 (10-30 μM; 4 days) increases ATM cleavage activity [1]. At 300 µM doses, GJ103 does not appear to be cytotoxic to AT cells [1].
In vivo activity data for GJ-103 free acid is not provided in the search results. Its potential as a therapeutic agent is based on its in vitro readthrough activity. Further studies are needed to confirm its in vivo efficacy. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for GJ-103 free acid are not specifically detailed. Its activity is assessed by measuring readthrough of premature stop codons, which is typically done using cell-based reporter assays.
|
| Cell Assay |
In vitro cell-based assays for GJ-103 free acid involve treating cells with the compound and measuring the production of full-length proteins from genes containing premature stop codons. Its anti-cancer activity is evaluated using cancer cell lines.
|
| Animal Protocol |
In vivo animal experiments for GJ-103 free acid have not been detailed in the available sources. As a research compound, its effects in animal models would be necessary to assess its potential for treating genetic disorders and cancer.
|
| ADME/Pharmacokinetics |
GJ-103 free acid has a molecular weight of 287.3 g/mol. It is also available as a sodium salt (CAS 1459687-96-7). Specific pharmacokinetic data is not provided in the search results.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is provided for GJ-103 free acid. As a research compound, its safety profile has not been fully characterized. Further studies would be required to determine its toxicity.
|
| References | |
| Additional Infomation |
GJ-103 free acid is a read-through compound that induces readthrough of premature stop codons and has potential for treating genetic disorders caused by nonsense mutations. It is an active analogue of GJ072 and is a research compound.
|
| Molecular Formula |
C16H14N4O3S
|
|---|---|
| Molecular Weight |
342.372361660004
|
| Exact Mass |
342.078
|
| Elemental Analysis |
C, 56.13; H, 4.12; N, 16.36; O, 14.02; S, 9.36
|
| CAS # |
1459687-89-8
|
| Related CAS # |
GJ103 sodium;1459687-96-7
|
| PubChem CID |
71748051
|
| Appearance |
Solid powder
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC(=C1)N2C(=NN=C2SCC(=O)O)C3=CC=CC=N3
|
| InChi Key |
2-((4-(3-methoxyphenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid
|
| InChi Code |
GBVQSAZHPCDBDY-UHFFFAOYSA-N
|
| Chemical Name |
GJ-103 free acid GJ103 GJ 103 GJ-103.
|
| Synonyms |
GJ-103 free acid; GJ103; GJ 103; GJ-103.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9208 mL | 14.6041 mL | 29.2082 mL | |
| 5 mM | 0.5842 mL | 2.9208 mL | 5.8416 mL | |
| 10 mM | 0.2921 mL | 1.4604 mL | 2.9208 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA